Literature DB >> 17403181

Current concepts in the pathogenesis of nonalcoholic fatty liver disease.

Nahum Méndez-Sánchez1, Marco Arrese, Daniel Zamora-Valdés, Misael Uribe.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of chronic liver disease, representing the leading cause of hepatology referral in some centres. However, its pathophysiology is not completely understood. Insulin resistance is one of the major mechanisms involved in disease prevalence and progression. Owing to the lack of an effective pharmacological therapy, recommendations on treatment are scarce and are based mainly on lifestyle changes, including diet and exercise. A review of the current literature on pathogenesis of NAFLD is presented in this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403181     DOI: 10.1111/j.1478-3231.2007.01483.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  61 in total

1.  Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.

Authors:  Xiang Wang; Weiping Li; Ying Zhang; Yang Yang; Guijun Qin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.

Authors:  Johannes Schmitt; Bo Kong; Grace L Guo; Andreas Geier; Bruno Stieger; Oliver Tschopp; Simon M Schultze; Monika Rau; Achim Weber; Beat Müllhaupt
Journal:  Liver Int       Date:  2014-02-07       Impact factor: 5.828

Review 3.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

4.  Interactions of central obesity with rs3918242 on risk of non-alcoholic fat liver disease: a preliminary case-control study.

Authors:  Pengbo Wu; Yonglong Hua; Shiyun Tan; Ming Li; Yongxiang Shu; Guo Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

5.  Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation.

Authors:  Bing Zhou; Dan-Li Zhou; Xiao-Hong Wei; Rong-Yu Zhong; Jie Xu; Liao Sun
Journal:  Acta Pharmacol Sin       Date:  2017-03-27       Impact factor: 6.150

6.  Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study.

Authors:  Jinzhou Zhu; Xingyong Wan; Yuming Wang; Kefu Zhu; Chunxiao Li; Chaohui Yu; Youming Li
Journal:  Endocrine       Date:  2016-09-14       Impact factor: 3.633

Review 7.  Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease.

Authors:  Andrea Tannapfel; Helmut Denk; Hans-Peter Dienes; Cord Langner; Peter Schirmacher; Michael Trauner; Berenike Flott-Rahmel
Journal:  Virchows Arch       Date:  2011-03-26       Impact factor: 4.064

8.  Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.

Authors:  Yueli Tian; Jingting Ma; Wudong Wang; Lingjuan Zhang; Jia Xu; Kai Wang; Dongfu Li
Journal:  Mol Cell Biochem       Date:  2016-09-09       Impact factor: 3.396

9.  Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?

Authors:  Priya Handa; Akhila Vemulakonda; Kris V Kowdley; Misael Uribe; Nahum Méndez-Sánchez
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

10.  Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease.

Authors:  Jung Won Yun; Yong Kyun Cho; Jung Ho Park; Hong Joo Kim; Dong Il Park; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Liver Int       Date:  2009-04       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.